期刊文献+

吡格列酮对非酒精性脂肪性肝病患者的氧化应激参数和炎症因子的影响

Effects of pioglitazone on oxidative stress-related parameters and inflammatory cytokines in patients with nonalcoholic fatty liver disease
原文传递
导出
摘要 目的:观察吡格列酮对非糖尿病非酒精性脂肪性肝病(NAFLD)患者肝脏脂肪含量及氧化应激参数和炎症因子水平的影响,探讨吡格列酮防治NAFLD的可能作用机制。方法:采用随机、单盲、对照组的研究。106例非糖尿病NAFLD患者随机分为吡格列酮组52例和对照组54例,对照组予以常规生活方式干预,吡格列酮组在常规生活方式干预的基础上予吡格列酮30 mg,1次/d,疗程均为24周。检测2组患者干预前后的肝/脾CT比值、血清丙氨酸转氨酶(ALT)、γ-谷氨酰转肽酶(GGT)、游离脂肪酸(FFA)、丙二醛(MDA)、4-羟壬烯醛(4-HNE)、白介素(IL)-1β、IL-6和肿瘤坏死因子(TNF)-α,用稳态模型评估胰岛素抵抗指数(HOMA-IR)。结果:治疗前2组各项指标均无显著差异(P>0.05)。对照组干预前后上述指标均无明显变化(均P>0.05)。吡格列酮组治疗后肝/脾CT比值明显升高(P<0.05),血清ALT、GGT、FFA、MDA、4-HNE、IL-1β、IL-6、TNF-α、HOMA-IR均明显下降(均P<0.05)。结论:吡格列酮治疗可以明显减轻NAFLD患者肝脏脂肪含量,降低NAFLD患者的氧化应激参数和炎症因子水平。 Objective To investigate the effect of pioglitazone on oxidative stress-related parameters and inflammatory cytokines in patients with nonalcoholic fatty liver disease (NAFLD). Methods In this randomized,single- blind,controlled study, 106 patients with NAFLD without diabetes were randomized into two groups. Fifty-two patients in the pioglitazone group received pioglitazone 30 mg/d with a course of 24 weeks, while the other 54 patients were served as controls. The levels of serum alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), free fatty acids (FFA), malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE), interleukin (IL)-lβ, IL-6, tumor necrosis factor-or (TNF-α), CT value ratio of liver and spleen, and homeostatic model assessment for insulin resistance (HOMA-IR) were measured before and after treatment. Results There were no significantly differences in baseline characteristics between two groups (P〉 0.05). After 24 weeks treatment,CT value ratio of liver and spleen increased (P〈0.05), and the levels of serum ALT, GGT, FFA, MDA, 4-HNE, IL-1β, IL-6, TNF-α and HOMA-IR decreased in pioglitazone group (all P〈0.05), and no obvious changes was observed in control group. No serious adverse reaction was observed in pioglitazone group. Conclusions Pioglitazone may decrease hepatic fat content and levels of oxidative stress-related parameters and inflammatory cytokines in patients with NAFLD.
出处 《内科理论与实践》 2013年第4期241-245,共5页 Journal of Internal Medicine Concepts & Practice
基金 上海市卫生局课题(项目编号:2009238)
关键词 吡格列酮 非酒精性脂肪性肝病 氧化应激 炎症因子 脾CT比值 Pioglitazone Nonalcoholic fatty liver disease Oxidative stress-related parameter Inflammatory eytokine CT value ratio of liver and spleen
  • 相关文献

参考文献16

  • 1Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH [J]. Clin Liver Dis, 2007, 11(1): 1- 16.
  • 2Papandreou D, Rousso I, Mavromichalis I. Update on non-alcoholic fatty liver disease in children [J]. Clin Nutr, 2007, 26(4): 409-415.
  • 3Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome- mediated dysbiosis regulates progression of NAFLD and obesity [J]. Nature, 2012, 482(7384): 179-185.
  • 4非酒精性脂肪性肝病诊疗指南(2006年2月修订)[J].现代消化及介入诊疗,2007,12(4):266-268. 被引量:56
  • 5Medina J, Fernandez-Salazar LI, Garcia-Buey L, et al. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis [J]. Diabetes Care, 2004, 27(8): 2057-2066.
  • 6WANG LiDong1, ZHOU Qi1, WEI JunPing1, YANG WanCai1, ZHAO Xin1, WANG LiXia1, ZOU Jian Xiang1, GAO ShanShan1, LI YongXin1 and YANG C.S.2Keywords esophageal neoplasms,apoptosis,precancerous lesions,Waf1 p21 gene,p53.Apoptosis and its relationship with cell proliferation,p53,Waf1p21,bcl-2 and c-mycin esophageal carcinogenesis studied with a high-risk population in northern China[J].World Journal of Gastroenterology,1998,4(4):15-21. 被引量:302
  • 7Chang CY, Argo CK, A1-Osaimi AM, et al. Therapy of NAFLD: antioxidants and cytoprotective agents [J]. J Clin Gastroenterol, 2006, 40 Suppl: S51-S60.
  • 8Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease [J]. Curr Opin Clin Nutr Metab Care, 2012, 15(6): 641-648.
  • 9Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications [J]. J Pediatr Gastroenterol Nutr, 2011, 53(2): 131-140.
  • 10Videla LA, Rodrigo R, Orellana M, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients [J]. Clin Sci (Lond), 2004, 106(3): 261-268.

二级参考文献2

共引文献356

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部